Moleculin Biotech (MBRX) said Thursday that certain holders of its existing warrants have agreed to exercise their holdings to purchase about 5.8 million shares of the company at a reduced exercise price of $1 per share.
The company said gross proceeds from the exercise of warrants is expected to total $5.8 million.
In consideration for the exercise of warrants for cash, Moleculin said it will issue new unregistered warrants to buy nearly 11.7 million shares, which will be immediately exercisable at $0.75 per share.
The transaction is expected to close by Friday and net proceeds would be used for working capital and general corporate purposes, the company said.
Price: 2.21, Change: +1.79, Percent Change: +426.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。